Commission omission - an update
This is an update to our previous post.
The Commission’s Pharmaceutical Committee discussed the NIVEL reports in October 2015. The notes of that meeting are available here. The reports themselves are attached clicking here and here. No further action has been announced, but the reports say that the value of summary headlines in product information are not yet supported by sufficient research, and this position was accepted by the Committee.